170900.KS Earnings — Dong-A ST Co., Ltd.

KSC

Updated Oct 29, 2026

Price —

Market Cap $327.7B

P/E -55.6

52W Range — – —

When is 170900.KS's next earnings date?

Dong-A ST Co., Ltd. (170900.KS) has not announced its next earnings date yet. Its most recent earnings report was on Friday, August 14, 2026.

How did 170900.KS do in its last earnings report?

In its most recent report on Aug 14, 2026, Dong-A ST Co., Ltd. posted EPS of $283.00. Revenue was $207.80B against a $208.75B estimate.

About Dong-A ST Co., Ltd.

Dong-A ST Co., Ltd. is a global enterprise focused on the research, development, production, and commercialization of a broad spectrum of pharmaceutical products and medical devices. The company's diverse portfolio of ethical drugs targets various medical conditions, including tuberculosis (with treatments like Closerin and Terizidone), neutropenia in chemotherapy patients (such as Dulastin and Leucostim), and anemia stemming from chronic renal failure (Eporon). Its robust oncology offerings feature Gemcit for cancers affecting the lung, pancreas, breast, bladder, and ovaries; Mainta for non-small cell lung cancer and malignant pleural mesothelioma; and Monotaxel, indicated for breast, prostate, head, neck, and gastric adenocarcinoma, among others. Additionally, Dong-A ST provides solutions for infertility and anovulation (Gonadopin), growth hormone deficiency and idiopathic short stature (Growtropin II), functional dyspepsia (Motilitone), gastritis (Stillen), diabetes (Suganon), and erectile dysfunction (Zydena). The company also actively participates in pharmaceutical licensing, encompassing both the acquisition and out-licensing of drugs. Its medical device segment includes advanced technological equipment, customized products, and specialized artificial cardiac circuit sets essential for complex open-heart surgeries. Dong-A ST Co., Ltd. was established in 1932 and is headquartered in Seoul, South Korea.

🤖 AI Earnings Analysis

Revenue of $202.9B missed the $216.2B estimate by $13.3B, a meaningful shortfall. With EPS, growth, and news unavailable, the evidence points to a weak quarter without a visible offset.

AI-generated summary — powered by BigEarnings.